在现实世界中评估sparsentan的药物安全框架
Wenjing Fu1, Jingyu Wang2, Yuzhou Xue3
1Department of Nephrology, Mianyang Central Hospital, Mianyang, China.
Renal failure
|February 20, 2025
概括
斯帕森坦在IgA脏病 (IgAN) 患者中显示出有利的安全概况. 对不良事件的分析显示,没有高优先级的临床事件,有助于优化药物使用和了解潜在的副作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药物监督 药物监督 药物监督
- 临床安全 临床安全
背景情况:
- 斯帕森坦已批准用于IgA脏病 (IgAN),以减少蛋白尿.
- 对斯帕森坦的综合药物安全性数据有限.
- IgAN是一种渐进的病,需要有效的治疗.
研究的目的:
- 评估sparsentan的药物安全框架.
- 使用现实数据识别新的不良事件信号.
- 评估临床优先事项和安全性的子组变化.
主要方法:
- 分析来自FDAAE报告系统的不良事件报告.
- 不成比例的分析来检测新的安全信号.
- 基于人口统计和临床因素的子组分析.
主要成果:
- 确定了两种新的器官系统类别和14个不良事件的首选术语.
- 低血压和头被归类为中度临床优先事件.
- 人口分析显示,男性,女性和不同年龄组的特定不良事件的风险各不相同.
结论:
- 斯帕森坦在IGAN患者中显示出良好的安全性.
- 在分析中没有确定任何高优先级的临床安全事件.
- 结果为优化sparsentan使用和管理潜在副作用提供了洞察力.
相关概念视频
Pharmacovigilance
768
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
768
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Structure-Activity Relationships and Drug Design
488
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
488
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Drug Control Governance: Regulatory Bodies and Their Impact
136
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
136


